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ABSTRACT
Over the past four decades, many studies have been
conducted on the toxicities of the rocket propellants
hydrazine (HZ) and monomethylhydrazine (MH).
Numerous technical challenges have made it difficult to
unambiguously interpret the results of these studies, and
there is considerable divergence between results obtained by
different investigators on the inhalation concentrations and
exposure durations required to produce a given toxic effect.
To determine the safe maximum acceptable concentrations
(MACs) for each toxic effect inducible by exposure to
hypergolic fuels in spacecraft atmospheres, NASA
undertook a critical review of published and unpublished
investigations on the toxicities of these compounds. The
quality of the data from each study was assessed based on
current state-of-the-art practices for similar studies. While
many questions remain unanswered, MACS were
determined using the best available data for a variety of toxic
endpoints for potential continuous exposure durations
ranging from 1 hour to 180 days. Spacecraft MACs
(SMACs) were set for each compound based on the most
sensitive toxic endpoint at each exposure duration.
INTRODUCTION
Payload and utility chemicals to be used or generated on
manned space flights are evaluated by toxicologists at NASA
for their potential health effects on crew members. For each
mission, toxicologic information summaries and brief hazard
assessments for each chemical flown are published as a
"Blue Book". In addition, SMACs are established for
individual priority airborne chemicals by NASA and
contractor toxicologists after in-depth toxicological
evaluations of the chemical. The SMAC documents include
summaries of the chemical, physical, pharmacokinetic, and
toxicological properties of each chemical and document the
rationale used to establish the SMAC values. The SMAC
values are used as guidelines to determine the levels of
containment needed for each chemical flown and the health
impact of a chemical release into the cabin atmosphere.
NASA has a policy to comply with maximum exposure
limits for the workplace (ground based operations)
established by other nationally recognized groups such as the
American Congress of Governmental Industrial Hygienists
(ACGIH) Threshold Limit Value (TLV ®) Committee. The
ACGIH, for example, promulgates recommended exposure
limits (TLVs) for airborne chemicals in the workplace
atmosphere, based on the typical occupational exposure
pattern, i.e. 8 h/day, 5 d/wk, for a working lifetime. This
exposure pattern is quite different from that experienced by
astronauts, i.e. continuous exposures for periods of up to
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one week, typically, and eventually up to 6 months or
longer. The TLVs, thus, are applicable for many ground-
based NASA operations. The recent announcement by the
ACGIH's TLV committee proposing to lower tke TLV for
HZ from 0.1 ppm to 0.01 ppm generated interest within
NASA and the U.S. Air Force due to the difficulty of rapidly
measuring 0.01 ppm. The stated basis for lowering the TLV
ten fold was a study( 11 which showed an increase in nasal
tumors at 50 ppb. However, the authors of the cited study
stated in their report that this result was not statistically
significant. At this same time, JSC toxicologists were
preparing SMAC documents on both HZ and MH. Based
on their review of the literature on HZ, some felt that the
scientific literature did not support lowering of the TLV
value. While safety should never be compromised, we
must also take into account the fact that limited resources
would be wasted if MACs for hypergolic fuels were set at
unnecessarily low values. A preliminary review of the
impact of lowering the current standards for safe levels of
these fuels indicates that important NASA and Air Fprce
operations could be restricted due to the need to:
1) revise current operating procedures for determining and
certifying that the work environment contains less than 10
ppb of either hydrazine,
2) develop instruments with enough sensitivity to measure
very low concentrations of fuels in real time, and
3) improve engineering controls to restrict exposure of
workers.
The following is a description of the process that the JSC
toxicologists used to evaluate the toxicological data available
in the literature for HZ and MH and to establish SMAC
values for these compounds.
PROCEDURE FOR SETTING SMAC VALUES
The information gathering phase of the SMAC setting
process involves a comprehensive review of the published
literature on the toxicity of the compound. This includes a
search of the computerized databases (e.g. Toxline, Toxlit,
Medline, etc.) for all articles on the toxicity and/or chemistry
of the compound. Abstracts of all relevant articles are
obtained and reviewed. The key articles are identified and
complete copies of the original articles are obtained
whenever possible. A toxicity table is compiled containing a
summary of the toxicity findings for inhalation exposures,
including species exposed, exposure durations and chemical
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concentrations,andtoxiceffectsobserved.If insufficient
dataisavailablefrominhalationexposures,toxicitydata
fromotherroutesofexposuremustbeused.
Theevaluationphaseinvolvesa determinationf the
biologicalendpointsofmostconcerna dacriticalreviewof
thequalityoftheavailabledata.Thecriteriausedtorankthe
toxicendpointsincludetheseverityofimmediateeffectson
crewperformance,whichcouldjeopardizemission-related
activities,andtheseverityoflongtermhealtheffectson
crewmembers.Thecriteriausedtojudgethequalityofthe
studiesincludesuchfactorsas:
Wasthechemicalpureandwasits concentration
determinedanalyticallyatfrequenti tervalsduring
exposure?Wastheexposurechamberoperatedaccordingto
acceptedguidelines?
Werethereconfoundingexposurestootheragents?
Wereasufficientumberofsubjectsexposed?
Weretheresufficientnumbersof appropriatecontrols
whichwereproperlyshamexposed?
Wereallthesubjects& controlshealthy(otherthan
treatment-relatedeff cts)?
Wererelevantendpointsexaminedafterappropriate
exposurep riods?
Basedonthesecriteria,thehighestquality,relevants udies
areidentifiedandusedasstartingpointstoderiveSMAC
values.
Theextrapolationphaseof theSMACsettingprocess
involvesextrapolationf datafromthekeystudiesto
relevanthumanexposureconditionstoobtainMACsfor
eachendpointofconcernatexposuredurationsof 1hr,24
hr,7 days,30daysand180days.Thus,eachexposure
durationmayhavemultipleMACs,eachbasedonone
biologicalendpointsuchascarcinogenesis,irritation,central
nervoussystemeffects,lethality,cardiovasculareffects,etc.
Theuseofadjustmentfactorsi oftenrequiredtoaccountfor
differencesinspecies,routesof administration,exposureduration,andeffectsof microgravity.Extrapolationto
untestedxposuredurationsis oftenbasedontheunproven,
butwidelyusedassumptionthathetoxicityofacompound
isalinearfunctionoftheproductoftheexposureduration,t,
andtheconcentrationofthecompound,c. If theproductof
c timest forvariousexposurescenariosisequivalent,then
equivalenttoxiceffectscanbeexpected.Thismethodof
extrapolationis otuniversallyapplicable,however,and
mustbeusedwithcaution.
ThevalueoftheMACforthemostsensitiveendpointis
selectedforeachexposuredurationtoestablishSMAC
values.Therationaleusedtosethese"INTERIM"SMAC
valuesi documentedalongwiththeinformationusedfrom
thekeystudies.
Thereviewphaseof theSMACsettingprocessinvolves
sendingtheINTERIMSMACdocumenttotheNational
ResearchCouncil'sCommitteeon Toxicologyfor
comments.Afterreturnof thedocumentbytheNRC's
COT,it is revisedasneededandanOFFICIALSMAC
established.
Thefollowingdescriptionsillustratehowtheprocess
describedabovewasappliedinestablishingSMACvaluesforftZandforMH.
HYDRAZINE
A computerized search of several toxicology-related
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databases identified numerous articles dealing with HZ and
related compounds. Of these, abstracts were reviewed for
65 articles whose titles indicated they would be of relevance
to setting SMAC values. Full copies were obtained for 29 of
these articles. Two of these articles proved to be key articles
on which the SMAC values were based.
HZ vapor is extremely irritating to the eyes, nose, and
throat. Quantitative worker exposure information, however,
is not available and/or cannot be estimated from the existing
published data (2). The median concentration of HZ
detectable by odor is 3-4 ppm (3). Inhalation can cause
dizziness, anorexia (4) and nausea. HZ can be absorbed
through the skin(5) or orally and can induce contact
dermatitis(6.7,8), neurological impairment (9' 10) and at a
dose of 10 mg/kg injected intraperitoneally for three days in
rodents, HZ induces kidney, lung, and liver damage (11).
Accidental human exposures to high, but unspecified doses
induced temporary blindness, and tremors (t2) and, in one
case involving 6 months of occupational contact exposure,
conjunctivitis, tremor, cough, fever, vomiting, diarrhea, and
death03) A two hour exposure to 1.0 to 2.0 rag/1 (7600 to
15200 ppm) of HZ vapors has been reported to induce
convulsions, respiratory arrest and death in mice and
ratsO0). The toxicity of multiple lower doses was
cumulative, but surviving animals recovered and lived
normal lifespans if exposure was discontinued. The LCs0
for a four hour exposure to HZ was 750 mg/m 3 for rats and
330 mg/m 3 for mice(3). Exposure to 1.0 ppm of HZ for 90
days was highly lethal to rats and mice and moderately lethal
(20%) to monkeys (14). HZ was fetotoxic in rats and mice at
5 mg/kg administered intraperitoneally and was teratogenic
in mice at 12 mg/kg. HZ was mutagenic in several test
systems(15, 16, 17) and induced sister chromatid exchanges in
vitro (18).
There are conflicting reports on HZ's carcinogenicity. The
National Institute of Environmental Health Sciences finds
that there is sufficient evidence for the carcinogenicity of HZ
in experimental animals, but inadequate evidence for its
carcinogenicity in humans(19). Inhaled HZ has been reported
to induce alveolargenic carcinomas in three of eight mice
exposed at 0.2 ppm(2°), nasal and bronchial tumors in rats at
1 ppm(21) (see Table 1 below), and nasal tumors in 16 of
160 hamsters exposed at 5 ppm (21). Unequivocally toxic
doses (up to 50 rag/l), however, administered in drinking
water for the lifetime of rats were only weakly
carcinogenic(22). In male rats (the most sensitive species
and sex) exposed by inhalation, tumors (which were
predominantly benign) appeared only late in life in animals
showing many other chronic toxic effects including a greatly
increased inflammatory response of the upper airways (21_.
An additional study would be extremely helpful. Only
scanty epidemiological data is available on HZ-related
cancers in humans(2). No excess risk of cancer has been
found in workers occupationally exposed to HZ vapors, but
the number of workers having substantial exposure has been
too few to detect anything other than gross hazards (23, 12).
Of the many toxic effects of HZ exposure, the ones of most
concern, for which quantitative data are available include
hepatotoxicity, carcinogenicity, and lethality. These effects
were evaluated and MACs were set for each endpoint at the
various exposure durations.
Hepatotoxicity:
Liver effects induced by airborne ttZ include focal liver cell
hyperplasiainfemaleratsexposedat1ppmHZfor2yrs
and"fattychanges"in theliverinseveralspeciesafter90
dayscontinuousexposureto0.8ppmHZ(25.t4).MAC
valuesforlivertoxicitywerecalculatedfor180d,30d,and7d. Theuseof the"concentrationtimestime"ruleto
extrapolatetoexposuretimesof24hrsorless(atwoorder
ofmagnitudeextrapolation)wasdeemedinappropriatefora
compoundsuchasHZ whichhassucha steepdose-
responsecurve.
Carcinogenicity:
HZ has been found to be carcinogenic in animal model
systems(21, 25, 17). The oncogenic changes were mostly
benign and observable only at the microscopic level, pro-
ducing little or no impairment of respiratory function and no
effect on life expectancy. The non-oncogenic toxicities of
HZ exposure in animals were more severe in producing
debilitation and lethal effects. There are, moreover, no
known reports of HZ-induced human tumors. Most human
exposures to HZ have been accidental or job-related and
dose-response data are not available. Although the data for a
carcinogenic effect of HZ are not compelling, prudence
requires that carcinogenicity be considered in determining a
MAC for HZ. MACs were calculated using the linearized
multistage model method described by the NRC(27)as
illustrated below.
Based on the data of MacEwen et at., the NRC Committee
on Toxicology (COT) calculated that the lower 95%
confidence limit on the inhalation dose that would produce a
1% lifetime tumor incidence in rats is 0.055 ppm for a 6
hr/day, 5 day/wk, 52 wk/yr, 1 yr exposure. This
extrapolates to 0.005 ppm for a continuous 2 yr exposure:
0.055 ppm x (6 hr/24 hr) x (5 hr/7 hr) x (1 yr/2 yr)
= 0.0(/5 ppm
Extrapolating the 1% tumor incidence from a continuous 2
year exposure at 0.005 ppm to a 24 hr exposure at the same
0.005 ppm concentration, the NRC COT estimated(28) the
tumor risk for rats should be no more than 10 .2.
The NRC has stated (29) that the linearized multistage model
is sufficiently conservative so that an additional species
extrapolation factor is unnecessary. Therefore, the
following equation, based on Crump and Howe's linearized
multistage model(27), was used to calculate the exposure
concentrations, D, which would yield a tumor risk of 10 -3
for exposure durations of 1 h, 24 h, 7 d, 30 d, and 180 d.:
D = (d) (25,600) k (10-3/risk + {25,600 - ((365)(age)) k }-
25,600 - ((365)(age) - exp) k
where
d is the the concentration during a lifetime exposure
(0.005 ppm in this case)
25,600 is the # of days in a 70 y human lifetime
k is the number of stages in the model
(3 in this case)
10 -3 is the acceptable risk level
age is the minimum age of an astronaut, in years
(30 in this case)
exp is the exposure duration, in days
(0.042, 1, 7, 30, or 180)
risk is the risk of tumor for lifetime exposure to d
(10 -2 in this case)
This equation yields the following values, rounded to one
significant figure:
300 ppm for I hr
10 ppm for 24 hr
2 ppm for 7 d
0.4 ppmfor 30d
0.07 ppmfor 180d
Analysis of the lethality data, except for very short
exposures, is difficult and frustrating. To set the l-h MAC,
we rely on the LCs0 data from an old report(8) that,
nonetheless, appears to be well done. The LCs0 for a 4-h
exposure was 570 ppm in rats and 250 ppm in mice. The
results for the more sensitive species (mouse) were adjusted
by the following factors: 250 ppm was divided by 10 for
inter-species extrapolation, again divided by 10 to
extrapolate from the LCs0 to a NOAEL, and multiplied by 2
to extrapolate from a 4-h exposure to a l-h exposure to yield
a 1-h MAC for lethality of 5 ppm. A factor of 10 was
judged to be adequate to go from the LCs0 to a NOAEL due
to the steepness of the dose response curve(30). The use of a
two-fold rather than a four-fold safety factor to extrapolate
from a 4 h exposure to a 1 h exposure is supported by
experimental results for a similar compound, MH(3°). The
24-h MAC is calculated similarly, but dividing by 6 to
extrapolate from a 4-h to a 24-h exposure to yield a 24-h
MAC value of 0.4 ppm. The use of the 'concentration times
time" rule for longer exposures is not considered appropriate
for the available acute data. To set lethality MACs for the
longer periods, we must turn to repeated intermittent
exposures available on multiple species.
The scatter in the lethality data for repeated exposures to HZ
is large and suggests serious shortcomings in some of the
study designs. An early report(3t) showed that at a nominal
concentration of 20,000 ppm, the recovery of HZ decreases
from 26% to 4% simply because of the presence of rat
bodies, whereas, if the rats are alive, the recovery is
decreased to 2%. This clearly indicates that a large fraction
of the airborne HZ adheres to the rat fur, probably about 10
times the amount retained in the respiratory system. Since
rats preen, much of their exposure to HZ may have been by
oral ingestion, rather than inhalation. The point is that the
rodent data are so scattered that the true susceptibility is
simply unknown.
In the study above(31), food was removed during exposures,
so that it was not contaminated with HZ. In some later
studies (32), food was not removed during exposure and the
rodents were found to be much more susceptible. For
example, an 8% mortality was seen in mice exposed to 1.0
ppm HZ for 6 h/d for 2 wk (60 ppm.h)< TM, whereas no
mortality was seen in mice exposed to 40 ppm HZ 6 h/d for
4 d (960 ppm.h)( TM.
Based on these studies, MACs were calculated for lethality,
carcinogenesis, and hepatotoxicity as described in the
procedure section.
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TABLE 1: MACs and Endpoints for HZ
Species Safely Factors ........... ._A.Q..(_p_m...} ...................................
EndDoint Tested _ NOAEL
Lethality (8) Mouse 10 10
LC5o=250 ppm, 4 h
Lethality (24) Monkey 10 10
0.8 ppm, 30 d contin.
Carcinogenesis(27) Rat 1 1
0.05 ppm, 1 yr, contin
Hepatotoxicity (24) Monkey 10 10 * * 0.1
0.78 ppm, 90d, contin. Rat, Mouse
...........................................................................................................
• N/A for use of"concentration times time" rule
t Calculated based on NRC COTs equation (27) derived from Crump &
Howe's multistage carcinogenicity model, using a lifetime cancer risk
of 103 .
L.ltt 24nr 2__a _
5 0.4 * * *
• * 0.08 0.02 0.003
300t 10t 2_ OAt 0.07 t
0.02 0.004
For each exposure duration, the SMAC was set equal to the
lowest MAC value among the three endpoints shown above.
The resulting values, in units of both ppm :rod mjm 3, are
listed along with the most sensitive target "oxicity at that
exposure duration.
TABLE 2: SMACS for ltZ
m__g/__m3 Ta:gct Toxi_;ity
1-h SMAC 5 13 Lethalk_,
24-h SMAC 0.4 0.5 Lethali_
7-d SMAC 0.08 0.10 Lethality, Hepatotoxicity
30-d SMAC 0.02 0.03 Lethality, Hepatotoxicity
180-d SMAC 0.003 0.004 l.cthality, Hepatotoxicity
* Temporary 7-d SMAC was set at 0.04 ppm
These SMAC values, except for 180 days continuous
exposure, are all above the 0.0l ppm "I'[,V proposed by
ACGIH. As will be shown below, the situation for MH is
quite different and highlights the need for better, more
definitive toxicological studies on this class of compounds.
METHYLHYDRAZINE
A computerized search of severa! toxicology-related
databases identified a large number of articles dealing with
MH and related compounds. Of these, abstracts were
reviewed for 173 articles whose titles indicated they would
be of relevance to setting SMAC values. Full copies were
obtained for 79 of these articles. In contrast to the situation
with HZ, the data for MH toxicity available from a study(33)
performed at NASA's White Sands Testing Facility proved
to be a key article which required the setting of the SMAC at
a very low value.
MH can induce a variety of toxic effects. The overt signs of
acute MH toxicity in mice, rats, dogs, and monkeys include
irritation of nose and eyes, blood discrasias (hemolytic
anemia and Heinz bodies in humans, monkeys and dogs)
salivation, emesis, diarrhea, hyperactivity, tremors and
severe tonic-clonic convulsions, which precede death. In
addition, chronic exposure to low concentrations of MH has
been shown to induce blood and liver effects in dogs and
cancer in mice and hamsters.
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A steep dose-mortality response curve was seen for all
species, regardless of the length of exposure. Of the species
tested, squirrel monkeys were the most sensitive to the lethal
effects of MH. Monkey Le50 experiments were performed,
examining three exposure times: 15, 30 and 60 min. and
using 25 monkeys, total. The lower confidence limit was
used for calculating the MAC based on the LCs0. This
yields a value which is lower than that obtained based on the
NOAEL, since no confidence limits were calculated for the
NOAEL. This anomaly is due to the steepness of the dose-
mortality response curve. A safety factor of 100 was used in
calculating the MACs for lethality due to the severity of the
endpoint.
Nasal lnj_ary:
The most sensitive endpoint for toxicity at concentrations
greater than or equal to the odor threshold was nasal injury.
Since the data for injury were obtained from human
subjects(32), no species conversion was required.
Nevertheless, since 75% of the subjects complained of
irritating odor and 28% developed significant nasal
pathology under the test conditions, the tested concentration
of 0.2 ppm must be lowered to a level which would be
anticipated to produce no adverse effects. A safety factor of
10 was used to estimate the NOAEL. An additional safety
factor of 10 was warranted to account for the fact that a
single sniff caused the observed effects, whereas the MACS
must be set to protect during continuous, much longer term
potential exposures. The resulting level of 0.002 ppm is less
than or equal to even the 180 day MACs for all other
endpoints. Since the endpoint is injury of the nasal mucosa,
and since no epidemiological data were available to indicate
that long term exposure to sub-irritating (short-term) levels
of MH would lead to cumulative effects, the MAC for nasal
injury was set at 0.002 ppm MH for all exposure durations.
It must be noted that the results of this NASA study do not
correlate with the results reported by others for exposure of
humans to MH (see Heinz bodies discussion below).
Nevertheless, a careful review of the data and methodology
showed that this study appeared to be well done and did not
reveal any basis on which this study could be discounted or
ignored.
Heinz Bodies:
The low level of Heinz bodies seen in human volunteers
exposed to 90 ppm MH for 10 min were not enough to
produce any noticeable symptoms of toxicity, and this
toxicity was completely reversible(35). MACs were not
calculated for exposure times longer than one hour, for the
reasons stated in the footnote to the table below.
Carcinogenesis:
The NRC COT (28) used the data of Kinkead et al. (34) as
input to the multistage model of Crump and Howe to obtain
a 95% lower confidence limit of 0.116 ppm for a lung tumor
risk in mice of 0.01, based on a work-week exposure
schedule. Using the "concentrations times time" rule to
convert to a continuous lifetime exposure yielded the value
of 0.01 ppm corresponding to a lifetime tumor risk of 0.01.
TABLE 3: MACs and Endpoints for MH
Specie
Endooint Tested
I
Lethality(30) Severe Monkey 100
LC6o, l hr = 82 +_16ppm
(2 ch'edl4exposed)
Lethality(30) NOAEL Monkey 100
NOAEL, 1 hr = 75 ppm
(0 ddedl2 exposed)
Nasal Injury(33) MOd Man 1
12/42 exposed to
0.2 ppm, 30 cc,
single sniff
Heinz Bodies (36) Mild Man 1
10 rain @ 90 ppm
Carcinogen(34) (b) MOd MiceCr&Howe
2 ppm, 1 yr, intermittent model
Liver Effects(35) NOAEL Dogs 10
0.04 ppm, 90 d, contin
Blood Effects( TM NOAEL Dogs 10
0.04 ppm, 90 d, contin
* N/A for use of"concentration times time" rule.
B1Q9;t Effects:
In continuous, 90 day low dose inhalation exposures of rats,
dogs and monkeys at 0.04 pm and 0.1 ppm, dogs showed
significant decreases in hematocrit hemoglobin levels and
blood cell count, but only at the higher dose (iT). MAC
values were calculated by applying Haber's rule and a safety
factor of 10 to the (NOAEL) 0.04 ppm level. Microgravity
should not affect the crewmembers' susceptibility to the
hemolytic effects of MH because mierogravity reduces the
total red cell mass, but the hematocrit remains at near normal
levels because the plasma volume is also reduced.
Using the equation for the linearized multistage model
shown above for HZ, MACs were calculated using a
continuous lifetime exposure to 0.01 ppm for which the
NRC COT calculated an upper 95% risk of 0.01. Because
the model is conservative, no safety factor is used to convert
animal test data to human exposure limits. Since it is not
anticipated that microgravity will affect humans' sensitivity
to the potential carcinogenic effects of MH, no adjustments
were made for microgravity-induced physiological changes.
In continuous, 90 day low dose inhalation exposures of rats,
dogs and monkeys at 0.04 pm and 0.1 ppm, dogs were the
• only species in which liver pathology was observed, and
only at the higher dose (35). MAC values were calculated
using Haber's rule and a safety factor of 10 to the NOAEL
level (0.04 ppm).
In order to determine which of these toxic end-points
should be used as the basis for setting the SMAC, MAC
values were determined for each endpoint at each of five
exposure durations. The results, tabulated below, were used
to select the value which provided the best protection.
Safety MAC _oom)
Vactor I 1 hr 2,_4___ 7__a 20__a
0.65 0.03 * * *
0.75 0.03 * * *
0.002 0.002 0.002 0.002 0.002
15 * * * *
* * 3.5 0.85 0.15
* * 0.05 0.012 0.002
* * 0.05 0.012 0.002
For each exposure duration, the SMAC was set equal to the
lowest MAC value among the endpoints shown above. The
resulting values, in units of both ppm and mg/m 3, are listed
along with the most sensitive target toxicity at that exposure
duration.
TABLE 4: SMACS for MH
Rllln mgLlll 3 Target Toxicity
1-h SMAC 0.002 0.004 Nasal Injury
24-h SMAC 0.002 0.004 Nasal Injury
7-d SMAC 0.002 0.004 Nasal Injury
30-d SMAC 0.002 0.004 Nasal Injury
180-d SMAC 0.002 0.004 Nasal Injury/Blood
Effects/Liver Effects
*Previous 7-d SMAC was 0.04 ppm.
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CONCLUSION
While one would intuitively expect that the toxicities of HZ
and MH would be similar, the SMAC values appear to
contradict this. We feel that this situation is an artifact of the
quality and type of studies which have been performed to
date. For MH, the SMAC values are based on the results of
a single study, which showed a much higher toxicity for MH
than all other studies we found. In spite of this
inconsistency, the study appears to be well done and its
results cannot be ignored. For HZ however, no similar test
has been performed, to our knowledge. Thus, no data are
available in the literature to support lowering the SMAC for
HZ to a value comparable to the SMAC for MH. The old
scientific refrain, "more work needs to be done", certainly
applies to toxicological studies of the hydrazines.
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CONCLUSION
While one would intuitively expect that the toxicities of HZ
and MH would be similar, the SMAC values appear to
contradict this. We feel that this situation is an artifact of the
quality and type of studies which have been performed to
date. For MH, the SMAC values are based on the results of
a single study, which showed a much higher toxicity for MH
than all other studies we found. In spite of this
inconsistency, the study appears to be well done and its
resuLts cannot be ignored. For HZ however, no similar test
has been performed, to our knowledge. Thus, no data are
available in the literature to support lowering the SMAC for
HZ to a value comparable to the SMAC for MH. The old
scientific refrain, "more work needs to be done", certainly
applies to toxicological studies of the hydrazines.
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